Zevra Therapeutics IncNASDAQ:ZVRA
- LAST PRICE9.4050
- TODAY'S CHANGE (%)-0.0850 (-0.8957%)
- Bid / Lots9.1000/ 1
- Ask / Lots9.7600/ 2
- Open / Previous Close9.5600 / 9.4900
- Day Range
- 52 Week Range
- Volume402,332
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZVRA |
|---|---|---|
| 09:32 ET | 4245 | 9.49 |
| 09:33 ET | 3164 | 9.66 |
| 09:35 ET | 7273 | 9.64 |
| 09:37 ET | 6009 | 9.74 |
| 09:39 ET | 3491 | 9.7 |
| 09:42 ET | 3100 | 9.701 |
| 09:44 ET | 2069 | 9.69 |
| 09:46 ET | 850 | 9.69 |
| 09:48 ET | 4305 | 9.615 |
| 09:50 ET | 255 | 9.62 |
| 09:51 ET | 2885 | 9.5901 |
| 09:53 ET | 500 | 9.575 |
| 09:55 ET | 3500 | 9.575 |
| 09:57 ET | 1036 | 9.575 |
| 10:00 ET | 500 | 9.61 |
| 10:02 ET | 200 | 9.57 |
| 10:04 ET | 100 | 9.575 |
| 10:06 ET | 3653 | 9.66 |
| 10:08 ET | 200 | 9.67 |
| 10:09 ET | 409 | 9.665 |
| 10:11 ET | 1000 | 9.63 |
| 10:15 ET | 1000 | 9.665 |
| 10:18 ET | 500 | 9.67 |
| 10:22 ET | 100 | 9.66 |
| 10:24 ET | 1000 | 9.64 |
| 10:26 ET | 100 | 9.63 |
| 10:27 ET | 100 | 9.615 |
| 10:31 ET | 600 | 9.666 |
| 10:33 ET | 590 | 9.68 |
| 10:36 ET | 600 | 9.66 |
| 10:38 ET | 11436 | 9.62 |
| 10:40 ET | 1637 | 9.61 |
| 10:44 ET | 500 | 9.62 |
| 10:47 ET | 700 | 9.6 |
| 10:49 ET | 1945 | 9.57 |
| 10:54 ET | 927 | 9.58 |
| 10:56 ET | 900 | 9.59 |
| 10:58 ET | 200 | 9.58 |
| 11:00 ET | 307 | 9.59 |
| 11:02 ET | 400 | 9.57 |
| 11:03 ET | 200 | 9.6 |
| 11:05 ET | 400 | 9.61 |
| 11:07 ET | 1275 | 9.585 |
| 11:09 ET | 822 | 9.62 |
| 11:12 ET | 534 | 9.58 |
| 11:14 ET | 1124 | 9.57 |
| 11:16 ET | 300 | 9.56 |
| 11:18 ET | 200 | 9.56 |
| 11:20 ET | 100 | 9.57 |
| 11:21 ET | 350 | 9.595 |
| 11:23 ET | 400 | 9.6 |
| 11:25 ET | 179 | 9.61 |
| 11:27 ET | 300 | 9.62 |
| 11:30 ET | 100 | 9.63 |
| 11:32 ET | 2104 | 9.65 |
| 11:34 ET | 1700 | 9.64 |
| 11:36 ET | 559 | 9.67 |
| 11:38 ET | 199 | 9.65 |
| 11:39 ET | 200 | 9.66 |
| 11:41 ET | 2357 | 9.695 |
| 11:43 ET | 200 | 9.69 |
| 11:45 ET | 1734 | 9.68 |
| 11:48 ET | 357 | 9.66 |
| 11:50 ET | 600 | 9.65 |
| 11:52 ET | 300 | 9.66 |
| 11:54 ET | 600 | 9.65 |
| 11:56 ET | 900 | 9.66 |
| 11:57 ET | 2851 | 9.65 |
| 11:59 ET | 664 | 9.65 |
| 12:01 ET | 1212 | 9.65 |
| 12:03 ET | 600 | 9.64 |
| 12:06 ET | 522 | 9.635 |
| 12:08 ET | 7101 | 9.63 |
| 12:10 ET | 2700 | 9.635 |
| 12:12 ET | 2155 | 9.64 |
| 12:14 ET | 500 | 9.63 |
| 12:15 ET | 300 | 9.635 |
| 12:17 ET | 422 | 9.635 |
| 12:19 ET | 727 | 9.635 |
| 12:21 ET | 1400 | 9.645 |
| 12:24 ET | 1733 | 9.63 |
| 12:26 ET | 152 | 9.635 |
| 12:28 ET | 700 | 9.63 |
| 12:30 ET | 310 | 9.63 |
| 12:32 ET | 300 | 9.63 |
| 12:33 ET | 731 | 9.635 |
| 12:35 ET | 1472 | 9.6 |
| 12:37 ET | 801 | 9.6018 |
| 12:39 ET | 900 | 9.575 |
| 12:42 ET | 960 | 9.55 |
| 12:44 ET | 2200 | 9.51 |
| 12:46 ET | 300 | 9.48 |
| 12:48 ET | 1400 | 9.505 |
| 12:50 ET | 100 | 9.51 |
| 12:53 ET | 100 | 9.515 |
| 12:55 ET | 100 | 9.515 |
| 01:00 ET | 564 | 9.535 |
| 01:02 ET | 100 | 9.535 |
| 01:04 ET | 100 | 9.545 |
| 01:06 ET | 200 | 9.545 |
| 01:08 ET | 1225 | 9.53 |
| 01:09 ET | 945 | 9.52 |
| 01:11 ET | 1490 | 9.475 |
| 01:13 ET | 873 | 9.49 |
| 01:15 ET | 100 | 9.49 |
| 01:18 ET | 3256 | 9.485 |
| 01:20 ET | 10961 | 9.525 |
| 01:22 ET | 3450 | 9.535 |
| 01:24 ET | 1052 | 9.52 |
| 01:26 ET | 474 | 9.53 |
| 01:27 ET | 100 | 9.535 |
| 01:29 ET | 200 | 9.52 |
| 01:31 ET | 100 | 9.51 |
| 01:33 ET | 200 | 9.51 |
| 01:36 ET | 187 | 9.525 |
| 01:38 ET | 1220 | 9.5 |
| 01:40 ET | 1299 | 9.47 |
| 01:42 ET | 7271 | 9.44 |
| 01:44 ET | 582 | 9.45 |
| 01:45 ET | 4300 | 9.4 |
| 01:47 ET | 600 | 9.43 |
| 01:49 ET | 369 | 9.42 |
| 01:51 ET | 3200 | 9.43 |
| 01:54 ET | 276 | 9.45 |
| 01:56 ET | 300 | 9.45 |
| 01:58 ET | 618 | 9.45 |
| 02:00 ET | 1000 | 9.435 |
| 02:02 ET | 732 | 9.455 |
| 02:03 ET | 600 | 9.47 |
| 02:05 ET | 400 | 9.45 |
| 02:07 ET | 817 | 9.475 |
| 02:09 ET | 363 | 9.47 |
| 02:12 ET | 1384 | 9.45 |
| 02:14 ET | 1950 | 9.46 |
| 02:16 ET | 100 | 9.46 |
| 02:18 ET | 1876 | 9.45 |
| 02:20 ET | 448 | 9.44 |
| 02:21 ET | 100 | 9.42 |
| 02:23 ET | 200 | 9.43 |
| 02:25 ET | 400 | 9.45 |
| 02:27 ET | 1100 | 9.455 |
| 02:30 ET | 1163 | 9.43 |
| 02:32 ET | 100 | 9.4302 |
| 02:34 ET | 128 | 9.43 |
| 02:36 ET | 700 | 9.43 |
| 02:38 ET | 100 | 9.45 |
| 02:39 ET | 300 | 9.455 |
| 02:41 ET | 817 | 9.44 |
| 02:43 ET | 100 | 9.445 |
| 02:45 ET | 1000 | 9.43 |
| 02:48 ET | 444 | 9.45 |
| 02:50 ET | 998 | 9.45 |
| 02:52 ET | 300 | 9.45 |
| 02:54 ET | 250 | 9.45 |
| 02:56 ET | 495 | 9.46 |
| 02:57 ET | 1775 | 9.48 |
| 02:59 ET | 621 | 9.48 |
| 03:01 ET | 447 | 9.49 |
| 03:03 ET | 4396 | 9.455 |
| 03:06 ET | 1225 | 9.45 |
| 03:08 ET | 1639 | 9.46 |
| 03:10 ET | 400 | 9.46 |
| 03:12 ET | 910 | 9.48 |
| 03:14 ET | 900 | 9.48 |
| 03:17 ET | 441 | 9.47 |
| 03:19 ET | 785 | 9.485 |
| 03:21 ET | 867 | 9.44 |
| 03:24 ET | 11750 | 9.42 |
| 03:26 ET | 13473 | 9.46 |
| 03:28 ET | 803 | 9.45 |
| 03:30 ET | 2200 | 9.4409 |
| 03:32 ET | 100 | 9.43 |
| 03:33 ET | 1392 | 9.44 |
| 03:35 ET | 1950 | 9.4 |
| 03:39 ET | 516 | 9.39 |
| 03:42 ET | 7900 | 9.4 |
| 03:44 ET | 1800 | 9.41 |
| 03:46 ET | 2747 | 9.43 |
| 03:48 ET | 1241 | 9.45 |
| 03:50 ET | 536 | 9.455 |
| 03:51 ET | 3551 | 9.46 |
| 03:53 ET | 3607 | 9.47 |
| 03:55 ET | 2687 | 9.47 |
| 03:57 ET | 800 | 9.46 |
| 04:00 ET | 38259 | 9.405 |
Today
Zevra Therapeutics to Participate at Upcoming Investor Conferences, from 10 hours ago by Dow Jones
10 hours ago by Dow Jones
Nov 21, 2024
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA(TM) (arimoclomol) for Treatment of Niemann-Pick Disease Type C, from 4:51PM ET on Thursday Nov 21, 2024 by Dow Jones
4:51PM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 20, 2024
DJ Zevra Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co., from 6:27AM ET on Wednesday Nov 20, 2024 by Dow Jones
6:27AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 14, 2024
DJ Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity, from 11:27AM ET on Thursday Nov 14, 2024 by Dow Jones
11:27AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
*DJ Zevra Therapeutics 3Q Rev $3.7M >ZVRA, from 5:39PM ET on Tuesday Nov 12, 2024 by Dow Jones
5:39PM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zevra Therapeutics Inc | 511.6M | -4.8x | --- |
CorMedix Inc | 604.3M | -12.2x | --- |
Eton Pharmaceuticals Inc | 290.1M | -58.3x | --- |
Elite Pharmaceuticals Inc | 658.9M | -100.4x | --- |
Cipla Ltd | 14.4B | 0.0x | --- |
Scilex Holding Co | 99.9M | -0.5x | --- |
Company Information
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Contact Information
- Headquarters
- 1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION, FL, United States 34747
- Phone
- 321-939-3416
- Fax
- 319-665-2577
Executives
- Independent Chairman of the Board
- Tamara Favorito
- President, Chief Executive Officer, Director
- Neil Mcfarlane
- Chief Financial Officer, Treasurer, Secretary
- R. LaDuane Clifton
- Chief People Officer
- Alison Peters
- Executive Vice President - Business Development, Chief Commercial Officer
- Joshua Schafer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $511.6M |
|---|---|
Revenue (TTM) | $24.8M |
Shares Outstanding | 53.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-1.96 |
Book Value | $1.49 |
P/E Ratio | -4.8x |
Price/Sales (TTM) | 20.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -348.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
